Quality of life is an important criterion for the efficiency of targeted therapy for metastatic skeletal involvement in breast cancer

Quality of life is an important criterion for the efficiency of targeted therapy for metastatic skeletal involvement in breast cancer

Assessment of quality of life is an important, valid, informative, and cost-effective procedure for evaluating the efficiency of treatment in patients with breast cancer metastasizing to the bone, receiving therapy with bone-modifying agents, including targeted therapy with denosumab. The administra...

Full description

Saved in:

Bibliographic Details
Main Authors:	T. Yu. Semiglazova, V. V. Semiglazov, L. V. Filatova, P. V. Krivorotko, V. V. Kolarkova, V. F. Semiglazov
Format:	Article
Language:	Russian
Published:	ABV-press 2014-07-01
Series:	Опухоли женской репродуктивной системы
Subjects:	quality of life breast cancer bone metastases skeletal-related events denosumab zoledronic acid
Online Access:	https://ojrs.abvpress.ru/ojrs/article/view/35
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of the effects of zoledronic acid versus denosumab on bone metabolism, inflammatory response, and immunoglobulins in breast cancer patients with bone metastases
by: Zhang Xian, et al.
Published: (2025-01-01)

Bone Metastases and Skeletal Complications: Information and Involvement of Patients with Cancer in the Treatment Pathway
by: Stefania Gori, et al.
Published: (2025-05-01)

Role of Denosumab and Zoledronic Acid in Geriatric Hip Fractures – A Comparative Analysis
by: P Madhuchandra, et al.
Published: (2024-01-01)

Treatment of myeloma bone disease: When, how often, and for how long?
by: Michael Tveden Gundesen, et al.
Published: (2025-06-01)

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
by: Roberta Scafetta, et al.
Published: (2025-08-01)

Current approaches to therapy for complications of bone metastases from breast cancer
by: L. G. Zhukova
Published: (2014-07-01)

Supra-Physiological Levels of Magnesium Counteract the Inhibitory Effect of Zoledronate on RANKL-Dependent Osteoclastogenesis
by: Lorenzo Caselli, et al.
Published: (2025-05-01)

Antiresorptive medication-related osteonecrosis of the jaw: Incidence and preventive measures utilization in cancer patients
by: Salman Ali Alabdali, et al.
Published: (2024-12-01)

A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy
by: İrem Öner, et al.
Published: (2025-02-01)

Time to initiation of antiresorptive agents in multiple myeloma to reduce skeletal related events
by: Amman Bhasin, et al.
Published: (2025-02-01)

Impacts of Prior Anti-Osteoporosis Treatments on Sequential Denosumab Responses in BMD Changes Among Postmenopausal Osteoporosis Women in East China: Real-World Data Analysis
by: Guan G, et al.
Published: (2025-05-01)

A study evaluating the risk factors and different treatment modalities for osteoporosis
by: Priya Madhuri Paspula, et al.
Published: (2025-03-01)

Clinical and biochemical efficacy zoledronic acid and denosumab combination: focus serum inflammatory factor level (serum ifcs), bone gla protein (bgp), and bone turnover markers b-collagen degradation product (b-ctx), and procollagen type 1 n-terminal propeptide (p1np)
by: Kong Lingyan, et al.
Published: (2025-01-01)

Efficacy evaluation of denosumab in the treatment of patients with postmenopausal osteoporosis at high risk of fracture
by: Jing ZHOU, et al.
Published: (2025-02-01)

ADJUVANT TREATMENT WITH BIPHOSPONATES IN COMPLEX THERAPY OF PAPILLARY THYROID CANCER BONE METASTASES
by: A. D. Kaprin, et al.
Published: (2017-09-01)

Target approach to treating osseous system pathology
by: M. B. Stenina, et al.
Published: (2014-08-01)

Comparative Evaluation of Two Different Single-Session Radiotherapy Regimens along with Zoledronic Acid in Painful Bone Metastases
by: Sanwaria Meenakshi, et al.
Published: (2024-09-01)

Skeletal Scintigraphy in Assesing the Response of Prostate Cancer Metastases to Androgen Deprivation Therapy
by: S. P. Mironov, et al.
Published: (2021-09-01)

First report of observation trial about impact of bisphosphonate`s treatment to the quality of life breast cancer patient with bone metastases
by: O. V. Zelenova, et al.
Published: (2014-07-01)

Zoledronate-induced orbital and ocular inflammation
by: Julia Dyrda, et al.
Published: (2025-03-01)

The association of human immunodeficiency virus and skeletal metastases in breast cancer using Tc-99m methyl diphosphonate bone scan
by: Masha Maharaj, et al.
Published: (2018-07-01)

Treatment of osteoporosis in clinical practice: first experience with the Russian generic drug of zoledronic acid
by: N. V. Toroptsova, et al.
Published: (2022-05-01)

Treatment of bone complications in multiple myeloma patients
by: V. V. Ptushkin
Published: (2022-11-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

Prevention Of Drug-Induced Osteonecrosis Of The Jaw In Cancer Patients
by: E. M. Spevak, et al.
Published: (2022-07-01)

Diagnosis of skeletal fragility due to Loeys-Dietz syndrome and treatment with romosozumab followed by denosumab
by: Yasutaka Tsujimoto, et al.
Published: (2025-06-01)

Optimal Timing of Bisphosphonate Administration in Combination with Samarium-153 Oxabifore in the Treatment of Painful Metastatic Bone Disease
by: Nigora Rasulova, et al.
Published: (2013-01-01)

BISPHOSPHONATES IN PROPHYLAXIS OF SKELETAL-RELATED ADVERSE EVENTS IN PATIENTS WITH CASTRATION-REFRACTORY PROSTATE CANCER
by: E. Yu. Safronova, et al.
Published: (2016-06-01)

EFFECT OF DENOSUMAB ON CLINICAL AND RADIOLOGICAL CHANGES IN RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS
by: P. S. Dydykina, et al.
Published: (2015-04-01)

Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factors
by: Suset Dueñas-Disotuar, et al.
Published: (2024-11-01)

Prostate-specific antigen as a risk factor for skeletal metastasis in native ethnic African Men with prostate cancer: A case-control study
by: Ayman Qureshi, et al.
Published: (2017-01-01)

Successful treatment of atypical femoral fracture with autogenous bone grafting in a patient on denosumab for bone metastasis from breast cancer: A case report
by: Taiki Yasukawa, et al.
Published: (2024-06-01)

Differences in interactions with the bone microenvironment between solid tumors and multiple myeloma: pathogenetic aspects. Possibilities and effectiveness of osteomodifying agents in multiple myeloma
by: A. V. Snegovoy, et al.
Published: (2021-04-01)

General St. Gallen-2015 guidelines for the treatment of early breast cancer (adapted by the experts of the Russian Society of Breast Oncologists)
by: V. F. Semiglazov, et al.
Published: (2015-09-01)

RETROSPECTIVE EVALUATION OF THE CLINICAL COURSE OF PAGET’S DISEASE OF BONE
by: Hülya Hacişahinoğulları, et al.
Published: (2023-10-01)

Zoledronic acid in the treatment of osteoporosis: indications for use
by: Nataliya Vladimirovna Toroptsova, et al.
Published: (2011-06-01)

Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases
by: G. A. Dashyan, et al.
Published: (2016-06-01)

Novel injectable composite incorporating denosumab promotes bone regeneration via bone homeostasis regulation
by: Guang Yang, et al.
Published: (2024-12-01)

Results of 2-year open multicenter observational study for efficacy, safety, tolerability and quality of life impact of zoledronic acid in women with postmenopausal osteoporosis in real-world settings in Russian Federation
by: O. M. Lesnyak, et al.
Published: (2021-06-01)

Time course of changes in bone resorption markers during pamidronate therapy in breast cancer patients with bone metastases
by: A. D. Petrova, et al.
Published: (2014-07-01)